Publication:

Vitiligo following alemtuzumab therapy in multiple sclerosis: a demonstration of secondary autoimmunity

Secondary autoimmunity is the most frequent adverse event that occurs in Relapsing and remitting multiple sclerosis (RRMS) patients who are being treated with alemtuzumab, however there have been few reported cases of autoimmune dermatologic conditions associated with alemtuzumab therapy. We report a case of a patient with RRMS who presented with depigmentation of the right lower cutaneous lip, consistent with vitiligo, seven months after her second treatment cycle with alemtuzumab. We emphasize the need for careful clinical surveillance of patients undergoing alemtuzumab therapy for rarely described secondary cutaneous autoimmune diseases.